Cancer immunotherapy in patients with preexisting autoimmune diseases.
We read with great interest the letter of Xie et al commenting on our article "Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study"(1). First, the authors suggested classifying Preexisting Autoimmune Diseases (PAD) according to systems, in order to assess if rheumatic disorders were more likely to flare with ICI. Such trend has been reported in other series, like Menzies et al and Leonardi et al, with the limit that the majority of the PAD in their cohort was a rheumatic disorder (n=27, 52% and n=25 (45%) respectively) (2,3).